Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson’s Disease
Abstract
:1. Introduction
2. Materials and Methods
2.1. Participants
2.2. Clinical Information
2.3. Serum and Saliva Collection and ELISA Analysis
2.4. Immunohistochemical Study of Submandibulary Glands
2.5. Histological Examination
2.6. Statistics and Ethics
3. Results
3.1. Participant Characteristics
3.2. Salivary and Serum Native αSyn
3.3. Salivary and Serum 3-Nitrotyrosine Proteins, and Nitrative Stress
3.4. 3-Nitrotyrosine-αSyn in the Submandibulary Gland
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Devic, I.; Hwang, H.; Edgar, J.S.; Izutsu, K.; Presland, R.; Pan, C.; Goodlett, D.R.; Wang, Y.; Armaly, J.; Tumas, V.; et al. Salivary α-synuclein and DJ-1: Potential biomarkers for Parkinson’s disease. Brain 2011, 134, e178. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stewart, T.; Sui, Y.T.; Gonzalez-Cuyar, L.F.; Wong, D.T.; Akin, D.M.; Tumas, V.; Aasly, J.; Ashmore, E.; Aro, P.; Ginghina, C.; et al. Cheek cell-derived α-synuclein and DJ-1 do not differentiate Parkinson’s disease from control. Neurobiol. Aging 2014, 35, 418–420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kang, W.; Chen, W.; Yang, Q.; Zhang, L.; Zhang, L.; Wang, X.; Dong, F.; Zhao, Y.; Chen, S.; Quinn, T.J.; et al. Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson’s disease patients. Sci. Rep. 2016, 6, 28143. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vivacqua, G.; Latorre, A.; Suppa, A.; Nardi, M.; Pietracupa, S.; Mancinelli, R.; Fabbrini, G.; Colosimo, C.; Gaudio, E.; Berardelli, A. Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson’s Disease. PLoS ONE 2016, 11, e0151156. [Google Scholar] [CrossRef] [Green Version]
- Vivacqua, G.; Suppa, A.; Mancinelli, R.; Belvisi, D.; Fabbrini, A.; Costanzo, M.; Formica, A.; Onori, P.; Fabbrini, G.; Berardelli, A. Salivary alpha-synuclein in the diagnosis of Parkinson’s disease and Progressive Supranuclear Palsy. Parkinsonism Relat. Disord. 2019, 63, 143–148. [Google Scholar] [CrossRef]
- Atik, A.; Stewart, T.; Zhang, J. Alpha-Synuclein as a Biomarker for Parkinson’s Disease. Brain Pathol. 2016, 26, 410–418. [Google Scholar] [CrossRef]
- Goldman, J.G.; Andrews, H.; Amara, A.; Naito, A.; Alcalay, R.N.; Shaw, L.M.; Taylor, P.; Xie, T.; Tuite, P.; Henchcliffe, C.; et al. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson’s disease Features. Mov. Disord. 2018, 33, 282–288. [Google Scholar] [CrossRef] [Green Version]
- Cao, Z.; Wu, Y.; Liu, G.; Jiang, Y.; Wang, X.; Wang, Z.; Feng, T. α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease. Neurosci. Lett. 2019, 696, 114–120. [Google Scholar] [CrossRef]
- Giasson, B.I.; Duda, J.E.; Murray, I.V.; Chen, Q.; Souza, J.M.; Hurtig, H.I.; Ischiropoulos, H.; Trojanowski, J.Q.; Lee, V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290, 985–989. [Google Scholar] [CrossRef]
- Ischiropoulos, H. Protein tyrosine nitration—An update. Arch. Biochem. Biophys. 2009, 484, 117–121. [Google Scholar] [CrossRef]
- Fernández, E.; García-Moreno, J.M.; Martín de Pablos, A.; Chacón, J. May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum α-synuclein serve for diagnosis of idiopathic Parkinson’s disease? Antioxid. Redox Signal. 2013, 19, 912–918. [Google Scholar] [CrossRef] [Green Version]
- Dickson, D.W.; Braak, H.; Duda, J.E.; Duyckaerts, C.; Gasser, T.; Halliday, G.M.; Hardy, J.; Leverenz, J.B.; Del Tredici, K.; Wszolek, Z.K.; et al. Neuropathological assessment of Parkinson’s disease: Refining the diagnostic criteria. Lancet Neurol. 2009, 8, 1150–1157. [Google Scholar] [CrossRef]
- Del Tredici, K.; Hawkes, C.H.; Ghebremedhin, E.; Braak, H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and idiopathic Parkinson’s disease. Acta Neuropathol. 2010, 119, 703–713. [Google Scholar] [CrossRef]
- Beach, T.G.; Adler, C.H.; Sue, L.I.; Vedders, L.; Lue, L.; White Iii, C.L.; Akiyama, H.; Caviness, J.N.; Shill, H.A.; Sabbagh, M.N.; et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010, 119, 689–702. [Google Scholar] [CrossRef] [Green Version]
- Del Tredici, K.; Braak, H. Lewy pathology and neurodegeneration in pre-motor Parkinson’s disease. Mov. Disord. 2012, 27, 597–607. [Google Scholar] [CrossRef]
- Vilas, D.; Iranzo, A.; Tolosa, E.; Aldecoa, I.; Berenguer, J.; Vilaseca, I.; Martí, C.; Serradell, M.; Lomeña, F.; Alós, L.; et al. Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: A case-control study. Lancet Neurol. 2016, 15, 708–718. [Google Scholar] [CrossRef]
- Paxinou, E.; Chen, Q.; Weisse, M.; Giasson, B.I.; Norris, E.H.; Rueter, S.M.; Trojanowski, J.Q.; Lee, V.M.; Ischiropoulos, H. Induction of α-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 2001, 21, 8053–8061. [Google Scholar] [CrossRef]
- Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.; Iwatsubo, T. Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4, 160–164. [Google Scholar] [CrossRef]
- Ischiropoulos, H.; Beckman, J.S. Oxidative stress and nitration in neurodegeneration: Cause, effect, or association? J. Clin. Investig. 2003, 111, 163–169. [Google Scholar] [CrossRef] [Green Version]
- Lebouvier, T.; Coron, E.; Chaumette, T.; Paillusson, S.; Bruley des Varannes, S.; Neunlist, M.; Derkinderen, P. Routine colonic biopsies as a new tool to study the enteric nervous system in living patients. Neurogastroenterol. Motil. 2010, 22, e11–e14. [Google Scholar] [CrossRef]
- Beach, T.G.; Adler, C.H.; Dugger, B.N.; Serrano, G.; Hidalgo, J.; Henry-Watson, J.; Shill, H.A.; Sue, L.I.; Sabbagh, M.N.; Akiyama, H.; et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J. Neuropathol. Exp. Neurol. 2013, 72, 130–136. [Google Scholar] [CrossRef] [Green Version]
- Navarro-Otano, J.; Gelpi, E.; Mestres, C.A.; Quintana, E.; Rauek, S.; Ribalta, T.; Santiago, V.; Tolosa, E. Alpha-synuclein aggregates in epicardial fat tissue in living subjects without parkinsonism. Parkinsonism Relat. Disord. 2013, 19, 27–31. [Google Scholar] [CrossRef] [Green Version]
- Gelpi, E.; Navarro-Otano, J.; Tolosa, E.; Gaig, C.; Compta, Y.; Rey, M.J.; Martí, M.J.; Hernández, I.; Valldeoriola, F.; Reñé, R.; et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov. Disord. 2014, 29, 1010–1018. [Google Scholar] [CrossRef]
- Aldecoa, I.; Navarro-Otano, J.; Stefanova, N.; Sprenger, F.S.; Seppi, K.; Poewe, W.; Cuatrecasas, M.; Valldeoriola, F.; Gelpi, E.; Tolosa, E. Alpha-synuclein immunoreactivity patterns in the enteric nervous system. Neurosci. Lett. 2015, 602, 145–149. [Google Scholar] [CrossRef]
- Souza, J.M.; Peluffo, G.; Radi, R. Protein tyrosine nitration—Functional alteration or just a biomarker? Free Radic. Biol. Med. 2008, 45, 357–366. [Google Scholar] [CrossRef]
- Mountcastle, V.B. Medical Physiology, 12th ed.; The C.V. Mosby Company: Saint Louis, MI, USA, 1977. [Google Scholar]
- Kang, U.J.; Goldman, J.G.; Alcalay, R.N.; Xie, T.; Tuite, P.; Henchcliffe, C.; Hogarth, P.; Amara, A.W.; Frank, S.; Rudolph, A.; et al. The BioFIND study: Characteristics of a clinically typical Parkinson’s disease biomarker cohort. Mov. Disord. 2016, 31, 924–932. [Google Scholar] [CrossRef]
- Niñerola-Baizán, A.; Gallego, J.; Cot, A.; Aguiar, P.; Lomeña, F.; Pavía, J.; Ros, D. Optimization of the reconstruction parameters in [(123)I]FP-CIT SPECT. Phys. Med. Biol. 2018, 63, 085009. [Google Scholar] [CrossRef]
- Chahine, L.M.; Iranzo, A.; Fernández-Arcos, A.; Simuni, T.; Seedorff, N.; Caspell-Garcia, C.; Amara, A.W.; Comella, C.; Högl, B.; Hamilton, J.; et al. Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder. NPJ Parkinsons Dis. 2019, 5, 2. [Google Scholar] [CrossRef]
- Martin-de-Pablos, A.; Córdoba-Fernández, A.; Fernández-Espejo, E. Analysis of neurotrophic and antioxidant factors related to midbrain dopamine neuronal loss and brain inflammation in the cerebrospinal fluid of the elderly. Exp. Gerontol. 2018, 110, 54–60. [Google Scholar] [CrossRef]
- Martín de Pablos, A.; García-Moreno, J.M.; Fernández, E. Does the Cerebrospinal Fluid Reflect Altered Redox State But Not Neurotrophic Support Loss in Parkinson’s Disease? Antioxid. Redox Signal. 2015, 23, 893–898. [Google Scholar] [CrossRef]
- Hernán, M.A.; Takkouche, B.; Caamaño-Isorna, F.; Gestal-Otero, J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann. Neurol. 2002, 52, 276–284. [Google Scholar] [CrossRef] [PubMed]
- O’Keefe, J.H.; Bhatti, S.K.; Patil, H.R.; DiNicolantonio, J.J.; Lucan, S.C.; Lavie, C.J. Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality. J. Am. Coll. Cardiol. 2013, 62, 1043–1051. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ragonese, P.; Salemi, G.; Morgante, L.; Aridon, P.; Epifanio, A.; Buffa, D.; Scoppa, F.; Savettieri, G. A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson’s disease. Neuroepidemiology 2003, 22, 297–304. [Google Scholar] [CrossRef] [PubMed]
- Tomlinson, C.L.; Stowe, R.; Patel, S.; Rick, C.; Gray, R.; Clarke, C.E. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 2010, 25, 2649–2653. [Google Scholar] [CrossRef]
- Ferreira, J.J.; Lees, A.; Rocha, J.F.; Poewe, W.; Rascol, O.; Soares-da-Silva, P. Bi-Park 1 investigators. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: A randomised, double-blind, controlled trial. Lancet Neurol. 2016, 15, 154–165. [Google Scholar] [CrossRef]
- Verber, D.; Novak, D.; Borovič, M.; Dugonik, J.; Flisar, D. EQUIDopa: A responsive web application for the levodopa equivalent dose calculator. Comput. Methods Progr. Biomed. 2020, 196, 105633. [Google Scholar] [CrossRef]
- Gibb, W.R.; Lees, A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 1988, 51, 745–752. [Google Scholar] [CrossRef] [Green Version]
- Galloway, P.G.; Mulvihill, P.; Perry, G. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am. J. Pathol. 1992, 140, 809–822. [Google Scholar]
- Lee, H.J.; Patel, S.; Lee, S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 2005, 25, 6016–6024. [Google Scholar] [CrossRef]
- Hartl, F.U. Protein Misfolding Diseases. Annu. Rev. Biochem. 2017, 86, 21–26. [Google Scholar] [CrossRef] [Green Version]
- Beach, T.G.; Serrano, G.E.; Kremer, T.; Canamero, M.; Dziadek, S.; Sade, H.; Derkinderen, P.; Corbillé, A.G.; Letournel, F.; Munoz, D.G.; et al. Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). J. Neuropathol. Exp. Neurol. 2018, 77, 793–802. [Google Scholar] [CrossRef]
- Iranzo, A.; Borrego, S.; Vilaseca, I.; Martí, C.; Serradell, M.; Sánchez-Valle, R.; Kovacs, G.G.; Valldeoriola, F.; Gaig, C.; Santamaria, J.; et al. α-Synuclein aggregates in labial salivary glands of idiopathic rapid eye movement sleep behavior disorder. Sleep 2018, 41, zsy101. [Google Scholar] [CrossRef]
- Shin, J.; Park, S.H.; Shin, C.; Kim, J.H.; Yun, T.J.; Kim, H.J.; Jeon, B. Submandibular gland is a suitable site for alpha synuclein pathology in Parkinson disease. Parkinsonism Relat. Disord. 2019, 58, 35–39. [Google Scholar] [CrossRef]
- Duda, J.E.; Lee, V.M.; Trojanowski, J.Q. Neuropathology of synuclein aggregates. J. Neurosci. Res. 2000, 61, 121–127. [Google Scholar] [CrossRef]
- Gao, H.M.; Kotzbauer, P.T.; Uryu, K.; Leight, S.; Trojanowski, J.Q.; Lee, V.M. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 2008, 28, 7687–7698. [Google Scholar] [CrossRef]
- Yu, Z.; Xu, X.; Xiang, Z.; Zhou, J.; Zhang, Z.; Hu, C.; He, C. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS ONE 2010, 5, e9956. [Google Scholar] [CrossRef]
IPD (n = 45) | Control (n = 30) | P | |
---|---|---|---|
Demographic and clinical parameters | |||
Age (years) | 61.4 ± 18.5 | 59.6 ± 11 | NS |
Gender, male n (%) | 27(60) | 12 (40) | NS |
Body mass index | 23.1 ± 2 | 24.8 ± 2.5 | NS |
Education (years) | 17.8 ± 2.1 | 17.3 ± 2.2 | NS |
Levodopa equivalent dose (mg per day) | 595.9 ± 650 | ||
Disease duration (years) | 9.9 ± 6.8 | ||
Age at IPD onset (years) | 57.9 ± 13.1 | ||
Hoehn-Yahr stage | 2.1 ± 0.8 | ||
Modified Schwab-England | 86 ± 25 | ||
MDS-UPDRS part III (on) | 24 ± 12 | ||
Total MDS-UPDRS (I-III) (on) | 37.2 ± 20 | ||
MDS-UPDRS part IV | 1.2 ± 2.4 | ||
Native αSyn concentration (pg/mL) | |||
Saliva | 361.9 ± 89 | 372.1 ± 91 | NS |
Serum | 244,789 ± 114,017 | 297,783 ± 110,992 | NS |
Saliva/serum αSyn ratio | 0.0015 ± 0.001 | 0.0013 ± 0.001 | NS |
3-Nitrotyrosine proteins concentration (µg/mL) | |||
Saliva | 0.35 ± 0.28 | 0.33 ± 0.27 | NS |
Serum | 1.52 ± 0.87 | 1.94 ± 1.23 | NS |
Saliva/serum 3-NT-proteins ratio | 0.27 ± 0.25 | 0.21 ± 0.15 | NS |
Parameters | Native αSyn | 3-Nitrotyrosine Proteins |
---|---|---|
Age (years) | 0.192 | 0.027 |
Body mass index | 0.215 | −0.058 |
Education (years) | 0.071 | −0.065 |
Levodopa equivalent dose (mg per day) | 0.166 | −0.209 |
Disease duration (years) | 0.044 | −0.098 |
Age at IPD onset (years) | −0.039 | 0.014 |
Hoehn-Yahr stage | 0.179 | 0.006 |
Modified Schwab-England | −0.102 | −0.161 |
MDS-UPDRS part III (on) | 0.048 | −0.107 |
Total MDS-UPDRS (I-III) (on) | 0.039 | −0.125 |
MDS-UPDRS part IV | 0.206 | −0.198 |
Demographic and Clinical Parameters | Patterns of Inclusions (Location) | |||||||
---|---|---|---|---|---|---|---|---|
Case | Gender | Age (y) | H-Y | Disease Duration (y) | “Lewy-Type” Inclusions (Interlobular Connective Tissue) | Coarse Aggregates (Interlobular Connective Tissue) | Small-Sized Bodies (Cytoplasm of Duct Cells) | Other Inclusions (Acinar Cells, Adipocytes, Endothelial or Blood Cells) |
PD1 | F | 76 | 2 | 6 | 1 | 2 | 4 | 0 |
PD2 | M | 73 | 2.5 | 8 | 2 | 2 | 3 | 0 |
PD3 | M | 56 | 2 | 6 | 2 | 2 | 3 | 0 |
PD4 | M | 55 | 2 | 7 | 2 | 2 | 4 | 0 |
PD5 | M | 70 | 1.5 | 5 | 1 | 0 | 4 | 0 |
PD6 | F | 71 | 2.5 | 7 | 2 | 1 | 3 | 0 |
CT1 | M | 66 | 0 | 2 | 4 | 0 | ||
CT2 | F | 55 | 0 | 2 | 3 | 0 | ||
CT3 | F | 47 | 0 | 0 | 4 | 0 | ||
CT4 | F | 66 | 0 | 2 | 4 | 0 | ||
CT5 | M | 77 | 0 | 2 | 3 | 0 | ||
CT6 | M | 60 | 0 | 0 | 3 | 0 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fernández-Espejo, E.; Rodríguez de Fonseca, F.; Suárez, J.; Tolosa, E.; Vilas, D.; Aldecoa, I.; Berenguer, J.; Damas-Hermoso, F. Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson’s Disease. Antioxidants 2021, 10, 715. https://doi.org/10.3390/antiox10050715
Fernández-Espejo E, Rodríguez de Fonseca F, Suárez J, Tolosa E, Vilas D, Aldecoa I, Berenguer J, Damas-Hermoso F. Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson’s Disease. Antioxidants. 2021; 10(5):715. https://doi.org/10.3390/antiox10050715
Chicago/Turabian StyleFernández-Espejo, Emilio, Fernando Rodríguez de Fonseca, Juan Suárez, Eduardo Tolosa, Dolores Vilas, Iban Aldecoa, Joan Berenguer, and Fátima Damas-Hermoso. 2021. "Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson’s Disease" Antioxidants 10, no. 5: 715. https://doi.org/10.3390/antiox10050715
APA StyleFernández-Espejo, E., Rodríguez de Fonseca, F., Suárez, J., Tolosa, E., Vilas, D., Aldecoa, I., Berenguer, J., & Damas-Hermoso, F. (2021). Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson’s Disease. Antioxidants, 10(5), 715. https://doi.org/10.3390/antiox10050715